Simmons Bank lessened its holdings in Celgene Co. (NASDAQ:CELG) by 0.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 19,627 shares of the biopharmaceutical company’s stock after selling 184 shares during the period. Simmons Bank’s holdings in Celgene were worth $2,549,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of CELG. Janus Henderson Group PLC increased its stake in Celgene by 4,290.5% in the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after buying an additional 8,217,433 shares in the last quarter. BlackRock Inc. increased its stake in Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. purchased a new stake in Celgene in the 2nd quarter worth $271,605,000. Arrowstreet Capital Limited Partnership increased its stake in Celgene by 1,489.2% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after buying an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares in the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.

Celgene Co. (NASDAQ:CELG) opened at $106.09 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a market cap of $80,881.07, a PE ratio of 16.05, a P/E/G ratio of 0.79 and a beta of 1.78.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the firm earned $1.58 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. research analysts expect that Celgene Co. will post 6.67 earnings per share for the current year.

In related news, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Corporate insiders own 0.95% of the company’s stock.

Several research analysts have commented on CELG shares. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Thursday, October 5th. BTIG Research reissued a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald reissued a “hold” rating and set a $112.00 price objective on shares of Celgene in a report on Monday, October 30th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a report on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $139.57.

TRADEMARK VIOLATION WARNING: “Simmons Bank Has $2.55 Million Holdings in Celgene Co. (CELG)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/simmons-bank-has-2-55-million-holdings-in-celgene-co-celg/1755011.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.